JP2017535600A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017535600A5 JP2017535600A5 JP2017543327A JP2017543327A JP2017535600A5 JP 2017535600 A5 JP2017535600 A5 JP 2017535600A5 JP 2017543327 A JP2017543327 A JP 2017543327A JP 2017543327 A JP2017543327 A JP 2017543327A JP 2017535600 A5 JP2017535600 A5 JP 2017535600A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- apilimod
- therapeutic agent
- vemurafenib
- melanoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 19
- 239000003814 drug Substances 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- GPXBXXGIAQBQNI-UHFFFAOYSA-N vemurafenib Chemical compound CCCS(=O)(=O)NC1=CC=C(F)C(C(=O)C=2C3=CC(=CN=C3NC=2)C=2C=CC(Cl)=CC=2)=C1F GPXBXXGIAQBQNI-UHFFFAOYSA-N 0.000 claims 8
- 229950002889 apilimod Drugs 0.000 claims 6
- 201000001441 melanoma Diseases 0.000 claims 6
- HSKAZIJJKRAJAV-KOEQRZSOSA-N n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 HSKAZIJJKRAJAV-KOEQRZSOSA-N 0.000 claims 6
- 229960003862 vemurafenib Drugs 0.000 claims 6
- 229960002621 pembrolizumab Drugs 0.000 claims 5
- 108010002350 Interleukin-2 Proteins 0.000 claims 4
- 102000000588 Interleukin-2 Human genes 0.000 claims 4
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 4
- 239000005536 L01XE08 - Nilotinib Substances 0.000 claims 4
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- HHZIURLSWUIHRB-UHFFFAOYSA-N nilotinib Chemical compound C1=NC(C)=CN1C1=CC(NC(=O)C=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)=CC(C(F)(F)F)=C1 HHZIURLSWUIHRB-UHFFFAOYSA-N 0.000 claims 4
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 4
- 239000013543 active substance Substances 0.000 claims 3
- BFSMGDJOXZAERB-UHFFFAOYSA-N dabrafenib Chemical compound S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 BFSMGDJOXZAERB-UHFFFAOYSA-N 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 229960003301 nivolumab Drugs 0.000 claims 3
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 claims 2
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 claims 2
- 108010058566 130-nm albumin-bound paclitaxel Proteins 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims 2
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 2
- 102000004243 Tubulin Human genes 0.000 claims 2
- 108090000704 Tubulin Proteins 0.000 claims 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 2
- 108700025316 aldesleukin Proteins 0.000 claims 2
- 229940100198 alkylating agent Drugs 0.000 claims 2
- 239000002168 alkylating agent Substances 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 2
- 229950002916 avelumab Drugs 0.000 claims 2
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 2
- 239000011230 binding agent Substances 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960004562 carboplatin Drugs 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- UKTAZPQNNNJVKR-KJGYPYNMSA-N chembl2368925 Chemical compound C1=CC=C2C(C(O[C@@H]3C[C@@H]4C[C@H]5C[C@@H](N4CC5=O)C3)=O)=CNC2=C1 UKTAZPQNNNJVKR-KJGYPYNMSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 2
- 229960004316 cisplatin Drugs 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 229960003901 dacarbazine Drugs 0.000 claims 2
- 229960003413 dolasetron Drugs 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229940080856 gleevec Drugs 0.000 claims 2
- 229960003727 granisetron Drugs 0.000 claims 2
- MFWNKCLOYSRHCJ-BTTYYORXSA-N granisetron Chemical compound C1=CC=C2C(C(=O)N[C@H]3C[C@H]4CCC[C@@H](C3)N4C)=NN(C)C2=C1 MFWNKCLOYSRHCJ-BTTYYORXSA-N 0.000 claims 2
- 229960002411 imatinib Drugs 0.000 claims 2
- 239000000138 intercalating agent Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229940083118 mekinist Drugs 0.000 claims 2
- 229960001346 nilotinib Drugs 0.000 claims 2
- 229960005343 ondansetron Drugs 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 229960002131 palonosetron Drugs 0.000 claims 2
- CPZBLNMUGSZIPR-NVXWUHKLSA-N palonosetron Chemical compound C1N(CC2)CCC2[C@@H]1N1C(=O)C(C=CC=C2CCC3)=C2[C@H]3C1 CPZBLNMUGSZIPR-NVXWUHKLSA-N 0.000 claims 2
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 2
- 229960002508 pindolol Drugs 0.000 claims 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 2
- 229940087463 proleukin Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- 229940081616 tafinlar Drugs 0.000 claims 2
- 229940069905 tasigna Drugs 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960004964 temozolomide Drugs 0.000 claims 2
- 229960004066 trametinib Drugs 0.000 claims 2
- 229960003048 vinblastine Drugs 0.000 claims 2
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 2
- 229940034727 zelboraf Drugs 0.000 claims 2
- 101000984753 Homo sapiens Serine/threonine-protein kinase B-raf Proteins 0.000 claims 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 claims 1
- 102100027103 Serine/threonine-protein kinase B-raf Human genes 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 229940034982 antineoplastic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims 1
- 229960002465 dabrafenib Drugs 0.000 claims 1
- 229960002448 dasatinib Drugs 0.000 claims 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 208000021039 metastatic melanoma Diseases 0.000 claims 1
- GAJWNIKZLYZYSY-OKUPSQOASA-N methanesulfonic acid;n-[(e)-(3-methylphenyl)methylideneamino]-6-morpholin-4-yl-2-(2-pyridin-2-ylethoxy)pyrimidin-4-amine Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CC1=CC=CC(\C=N\NC=2N=C(OCCC=3N=CC=CC=3)N=C(C=2)N2CCOCC2)=C1 GAJWNIKZLYZYSY-OKUPSQOASA-N 0.000 claims 1
- 239000002777 nucleoside Substances 0.000 claims 1
- 150000003833 nucleoside derivatives Chemical class 0.000 claims 1
- 239000006186 oral dosage form Substances 0.000 claims 1
- 229910052697 platinum Inorganic materials 0.000 claims 1
- 239000003909 protein kinase inhibitor Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 229940068117 sprycel Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077127P | 2014-11-07 | 2014-11-07 | |
| US62/077,127 | 2014-11-07 | ||
| US201562115228P | 2015-02-12 | 2015-02-12 | |
| US62/115,228 | 2015-02-12 | ||
| US201562119540P | 2015-02-23 | 2015-02-23 | |
| US62/119,540 | 2015-02-23 | ||
| PCT/US2015/059502 WO2016073871A1 (en) | 2014-11-07 | 2015-11-06 | Apilimod for use in the treatment of melanoma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535600A JP2017535600A (ja) | 2017-11-30 |
| JP2017535600A5 true JP2017535600A5 (enExample) | 2018-12-13 |
| JP6768682B2 JP6768682B2 (ja) | 2020-10-14 |
Family
ID=54548301
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543327A Expired - Fee Related JP6768682B2 (ja) | 2014-11-07 | 2015-11-06 | メラノーマの処置に使用するためのアピリモド |
| JP2017543330A Expired - Fee Related JP6716585B2 (ja) | 2014-11-07 | 2015-11-06 | 結腸直腸癌の処置に使用するためのアピリモド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017543330A Expired - Fee Related JP6716585B2 (ja) | 2014-11-07 | 2015-11-06 | 結腸直腸癌の処置に使用するためのアピリモド |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20190209576A1 (enExample) |
| EP (3) | EP3215157B8 (enExample) |
| JP (2) | JP6768682B2 (enExample) |
| KR (2) | KR20170098813A (enExample) |
| CN (2) | CN107427522B (enExample) |
| AU (2) | AU2015342876B2 (enExample) |
| BR (2) | BR112017009000A2 (enExample) |
| CA (2) | CA2966334A1 (enExample) |
| ES (1) | ES2734081T3 (enExample) |
| HU (1) | HUE044153T2 (enExample) |
| IL (2) | IL251904B (enExample) |
| MX (2) | MX374385B (enExample) |
| PL (1) | PL3215157T3 (enExample) |
| PT (1) | PT3215157T (enExample) |
| RU (2) | RU2731908C2 (enExample) |
| WO (2) | WO2016073871A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2016134406A (ru) | 2014-01-24 | 2018-03-01 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
| GB201408100D0 (en) * | 2014-05-07 | 2014-06-18 | Sec Dep For Health The | Detection method |
| US10206910B2 (en) | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| BR112018009738A2 (pt) * | 2016-01-21 | 2018-12-04 | Lam Therapeutics Inc | biomarcadores para tratamento contra o câncer com apilimod |
| RU2019113752A (ru) * | 2016-10-12 | 2020-11-13 | ЭйАй ТЕРАПЬЮТИКС, ИНК. | Композиции апилимода и способы их применения при лечении болезни альцгеймера |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| AU2019223014B2 (en) | 2018-02-21 | 2024-10-17 | Orphai Therapeutics Inc. | Combination therapy with apilimod and glutamatergic agents |
| US12589097B2 (en) | 2018-02-21 | 2026-03-31 | OrphAl Therapeutics Inc. | Apilimod compositions and methods of use |
| CA3167339A1 (en) | 2020-01-13 | 2021-07-22 | Verge Analytics, Inc. | Substituted pyrazolo-pyrimidines and uses thereof |
| IL309143A (en) * | 2021-06-11 | 2024-02-01 | Orphai Therapeutics Inc | Stabilized apilimod compositions and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6693097B2 (en) * | 2001-11-30 | 2004-02-17 | Synta Pharmaceuticals Corp. | Pyrimidine compounds |
| WO2005076843A2 (en) | 2004-02-06 | 2005-08-25 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating tumors and metastatic disease |
| US7745436B2 (en) * | 2004-04-13 | 2010-06-29 | Synta Pharmaceuticals Corporation | Disalt inhibitors of IL-12 production |
| WO2006029385A2 (en) | 2004-09-08 | 2006-03-16 | Chelsea Therapeutics, Inc. | Quinazoline derivatives as metabolically inert antifolate compounds. |
| WO2006053112A1 (en) | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Process for preparing trisubstituted pyrimidine compounds |
| US7863270B2 (en) * | 2005-05-13 | 2011-01-04 | Synta Pharmaceuticals Corp. | IL-12 modulatory compounds |
| WO2006128129A2 (en) * | 2005-05-26 | 2006-11-30 | Synta Pharmaceuticals Corp. | Method for treating cancer |
| ES2436877T3 (es) | 2005-11-17 | 2014-01-07 | OSI Pharmaceuticals, LLC | Intermedios para la preparación de inhibidores de mTOR bicíclicos condensados |
| HUE032274T2 (en) | 2006-07-12 | 2017-09-28 | Univ Tennessee Res Found | Substituted acetanilides and methods of their application |
| RU2438664C2 (ru) * | 2007-05-15 | 2012-01-10 | Пирамал Лайф Сайнсиз Лимитед | Синергическая фармацевтическая комбинация для лечения рака |
| US8402515B2 (en) | 2010-05-06 | 2013-03-19 | Jonathan Weizman | Apparatus and method for establishing a peer-to-peer communication session with a client device |
| WO2011146727A1 (en) * | 2010-05-19 | 2011-11-24 | Philip Bosch | Methods of treating interstitial cystitis |
| WO2013152342A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| US9295731B2 (en) * | 2013-04-01 | 2016-03-29 | Mark Quang Nguyen | Cleavable drug conjugates, compositions thereof and methods of use |
| RU2016134406A (ru) * | 2014-01-24 | 2018-03-01 | Лэм Терапьютикс, Инк. | Композиции апилимода и способы их применения |
| US10206910B2 (en) * | 2014-11-07 | 2019-02-19 | Lam Therapeutics, Inc. | Apilimod for use in the treatment of renal cancer |
| EP3253389A4 (en) * | 2015-02-03 | 2018-07-18 | LAM Therapeutics, Inc. | Apilimod compositions and methods for using same |
| US20180078561A1 (en) * | 2015-03-31 | 2018-03-22 | Lam Therapeutics, Inc. | Active metabolites of apilimod and uses thereof |
| TWI746449B (zh) * | 2015-07-20 | 2021-11-21 | 美商Ａｉ治療公司 | 使用阿吡莫德治療癌症之方法 |
-
2015
- 2015-11-06 PT PT15795317T patent/PT3215157T/pt unknown
- 2015-11-06 JP JP2017543327A patent/JP6768682B2/ja not_active Expired - Fee Related
- 2015-11-06 KR KR1020177015389A patent/KR20170098813A/ko not_active Ceased
- 2015-11-06 HU HUE15795317A patent/HUE044153T2/hu unknown
- 2015-11-06 CN CN201580072613.9A patent/CN107427522B/zh not_active Expired - Fee Related
- 2015-11-06 US US15/524,846 patent/US20190209576A1/en not_active Abandoned
- 2015-11-06 BR BR112017009000A patent/BR112017009000A2/pt not_active Application Discontinuation
- 2015-11-06 MX MX2017006019A patent/MX374385B/es active IP Right Grant
- 2015-11-06 WO PCT/US2015/059502 patent/WO2016073871A1/en not_active Ceased
- 2015-11-06 AU AU2015342876A patent/AU2015342876B2/en not_active Ceased
- 2015-11-06 ES ES15795317T patent/ES2734081T3/es active Active
- 2015-11-06 CA CA2966334A patent/CA2966334A1/en not_active Abandoned
- 2015-11-06 JP JP2017543330A patent/JP6716585B2/ja not_active Expired - Fee Related
- 2015-11-06 EP EP15795317.5A patent/EP3215157B8/en not_active Not-in-force
- 2015-11-06 RU RU2017119064A patent/RU2731908C2/ru active
- 2015-11-06 KR KR1020177015387A patent/KR20170101907A/ko not_active Ceased
- 2015-11-06 CA CA2966356A patent/CA2966356A1/en not_active Abandoned
- 2015-11-06 WO PCT/US2015/059526 patent/WO2016073884A1/en not_active Ceased
- 2015-11-06 PL PL15795317T patent/PL3215157T3/pl unknown
- 2015-11-06 MX MX2017006026A patent/MX2017006026A/es unknown
- 2015-11-06 EP EP15795319.1A patent/EP3215159B1/en active Active
- 2015-11-06 US US15/524,841 patent/US10765682B2/en active Active
- 2015-11-06 AU AU2015342863A patent/AU2015342863B2/en not_active Ceased
- 2015-11-06 BR BR112017009265A patent/BR112017009265A2/pt not_active Application Discontinuation
- 2015-11-06 EP EP21186071.3A patent/EP3954375A1/en not_active Withdrawn
- 2015-11-06 RU RU2017119066A patent/RU2739992C2/ru active
- 2015-11-06 CN CN201580072610.5A patent/CN107206090A/zh active Pending
-
2017
- 2017-04-24 IL IL251904A patent/IL251904B/en active IP Right Grant
- 2017-04-24 IL IL251903A patent/IL251903B/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017119064A (ru) | Композиции апилимода и способы его использования при лечениии меланомы | |
| JP2017533963A5 (enExample) | ||
| JP2016525097A5 (enExample) | ||
| JP2017535601A5 (enExample) | ||
| JP2013507415A5 (enExample) | ||
| JP2025111571A5 (enExample) | ||
| ES2667958T3 (es) | Crenolanib para el tratamiento de trastornos proliferativos que tienen FLT3 mutado | |
| JP2008528469A5 (enExample) | ||
| JP2017528475A5 (enExample) | ||
| JP2016508134A5 (enExample) | ||
| JP2014532647A5 (enExample) | ||
| JP2016533366A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2014065696A5 (enExample) | ||
| RU2016129953A (ru) | Фармацевтические комбинации | |
| JP2015500884A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| IL257847A (en) | Derivatives of 8– [6– [3 [- (amino) propoxy] –3 – pyridyl] –1 – isopropyl – imidazo [4, 5 –c] quinoline – 2 – ion as selective kinases of kinase atm for cancer treatment | |
| NZ607060A (en) | Substituted imidazoquinoline derivatives as kinase inhibitors | |
| KR20140040770A (ko) | 암 치료에 사용하기 위한 cdk4/6 억제제 및 pi3k 억제제를 포함하는 조합 요법 | |
| JP2011503071A5 (ja) | ヨードニトロベンズアミド化合物と抗腫瘍剤の組み合わせによる卵巣がんの治療 | |
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| JP2015516392A5 (enExample) | ||
| RU2016141569A (ru) | Комбинации | |
| JP2012524731A5 (enExample) |